Alopecia includes male or female pattern baldness, alopecia areata, telogen effluvium, and anagen effluvium. Creams, oils, lotions, shampoos, and foam formulations of topical alopecia medications are meant to be applied to the scalp in alopecia treatment.
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/3958
Increasing clinical trials in the treatment of alopecia are expected to fuel the growth of the Asia Pacific alopecia market over the forecast period. For instance, Concert Pharmaceuticals Inc. published new data analyses from its Phase 2 dose-ranging clinical trial of CTP 543 for the treatment of moderate-to-severe alopecia areata in June 2020.
Hair loss treatments’ side effects are likely to stifle market development. Some of the most common side effects include scalp inflammation, facial hair growth in women, sexual problems such as erectile dysfunction, and skin thinning.
The major factor driving the growth of the global Asia Pacific alopecia treatment market during the forecast period include the increasing prevalence of alopecia and consumer perception towards having good aesthetics.
Asia Pacific alopecia treatment market was valued at US$ 2,030.5 Mn in 2019 and is forecast to reach a value of US$ 3,214.8 Mn by 2027 at a CAGR of 6.8% between 2020 and 2027.
Asia Pacific alopecia treatment market is estimated to account for US$ 4,060.9 Mn in terms of value and is expected to reach US$ 6,427.7 Mn by the end of 2027
In terms of value, Alopecia Areata led the Asia Pacific alopecia care market in 2019, accounting for 65.8% of the market, followed by Alopecia Totalis and Alopecia Universalis. The segment’s growth is being aided by an increase in product launches for the treatment of alopecia and an increase in the incidence of alopecia areata.
Major players in the market are focused on conducting clinical trials for the treatment of alopecia. For instance, Pfizer, Inc. has five unique immunokinase inhibitors in late-stage clinical trials for the potential treatment of ten immune-mediated diseases as of June 2020, one of which is PF-06651600, an oral JAK3/TEC family kinase inhibitor in phase 3 clinical trial for the potential treatment of alopecia areata.
A new study has discovered a connection between androgenetic alopecia and the severity of COVID-19 disease. Antiandrogen therapy may be used as a treatment for COVID19 patients, according to a review published in May 2020 in Drug Development Research – Wiley Online Library titled “Androgen exposure gateway to COVID19 disease severity.”
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/3958
The Industrial Chemicals (Notification and Assessment) Act of 1989 governs the notification and assessment of industrial chemicals. The National Industrial Chemicals Notification and Assessment Scheme is in charge of enforcing this law (NICNAS). The Act provides legal protection for the Cosmetics Standard 2007, which is backed up by the NICNAS Cosmetic Guidelines 2007.
Major players operating in the Asia Pacific alopecia market include Shiseido Co., Ltd., Concert Pharmaceuticals, Inc., Follica, Inc., REVIAN Inc., Incyte, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Johnson & Johnson, Inc., Pfizer, Inc., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Cellmid Ltd., The Himalaya Drug Company, Taisho Pharmaceutical Holdings Co., Ltd., Histogen, Inc., and Zhangguang 101 Science & Technology Co., Ltd.
In January 2020, Concert Pharmaceuticals, Inc. received a patent from the U.S. Patent and Trademark Office for its investigational treatment for alopecia areata
In January 2020, REVIAN Inc. announced that final data from a randomized, double-blind study of the REVIAN RED hair growth system was presented at the 2020 Winter Clinical Dermatology Conference – Hawaii.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027